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Abstract
Myxoid liposarcomas (MLS), malignant tumors of adipocyte origin,
are driven by the FUS-DDIT3 fusion gene encoding an aberrant tran-
scription factor. The mechanisms whereby FUS-DDIT3 mediates
sarcomagenesis are incompletely understood, and strategies to
selectively target MLS cells remain elusive. Here we show, using an
unbiased functional genomic approach, that FUS-DDIT3-expressing
mesenchymal stem cells and MLS cell lines are dependent on YAP1, a
transcriptional co-activator and central effector of the Hippo path-
way involved in tissue growth and tumorigenesis, and that increased
YAP1 activity is a hallmark of human MLS. Mechanistically, FUS-
DDIT3 promotes YAP1 expression, nuclear localization, and transcrip-
tional activity and physically associates with YAP1 in the nucleus of
MLS cells. Pharmacologic inhibition of YAP1 activity impairs the
growth of MLS cells in vitro and in vivo. These findings identify
overactive YAP1 signaling as unifying feature of MLS development
that could represent a novel target for therapeutic intervention.
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Introduction
Myxoid liposarcomas (MLS) account for 5–10% of soft-tissue sarco-
mas and approximately 20% of malignant adipocytic tumors
(Fletcher et al, 2013). In the majority of cases, MLS arises in
younger adults, thus representing the most frequent liposarcoma
subtype in patients below the age of 20 years. Clinically, MLS are
characterized by a high rate of local recurrence and development of
distant metastases in approximately 40% of patients (Dei Tos,
2014). Morphologically, MLS comprise a broad spectrum of
subtypes ranging from paucicellular myxoid tumors to hypercellu-
lar, round-cell high-grade sarcomas associated with a more aggres-
sive clinical course (Antonescu et al, 2001). Genetically, the vast
majority of MLS are characterized by a t(12;16)(q13;p11) chromoso-
mal translocation that juxtaposes parts of the FUS gene to the entire
coding sequence of DDIT3. The resulting FUS-DDIT3 fusion protein,
which acts as a transcriptional (dys-)regulator, has been shown to
play an essential role in MLS pathogenesis (Kuroda et al, 1997;
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Figure 1. Identification of genes required by FUS-DDIT3-expressing mesenchymal stem cells.
A Schematic of RNAi screens. SCP-1 cells expressing FUS-DDIT3 or EV were transduced with Module 1 of the DECIPHER Pooled Lentiviral Human Genome-Wide shRNA
Library. Half of the cells were harvested on day 3 (baseline sample) and day 12 (drop-out sample), respectively, and shRNA abundance was determined by next-
generation sequencing (NGS).
B RIGER analysis to identify genes that are preferentially essential in FUS-DDIT3-expressing SCP-1 cells. EV-transduced SCP-1 cells and 20 FUS-DDIT3-negative cancer
cell lines screened with the same shRNA library were used as reference set. Genes were ranked according to relative shRNA depletion, and YAP1 was identified as top
FUS-DDIT3-specific essential gene. NES, normalized enrichment score.
C LFC change in YAP1 shRNA representation in 20 cancer cell lines and SCP-1 cells transduced with FUS-DDIT3 or EV. Black dots and error bars represent the
mean  SD of LFC scores for six independent shRNAs.
D Competition assays with SCP-1 cells transduced with RFP-labeled NTC or YAP1 shRNAs. Flow cytometric quantification of RFP-positive cells on day 9 relative to day 3
showed that YAP1 knockdown was preferentially toxic to FUS-DDIT3-expressing cultures. Bars and error bars represent the mean  SD of two independent
experiments, two-way ANOVA.
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Perez-Losada et al, 2000; Engstrom et al, 2006; Riggi et al, 2006),
but its mode of action remains incompletely understood.
Long-term survival in MLS patients may be achieved through
radical surgery and adjuvant radiation and/or conventional
chemotherapy (Jones et al, 2005; Ratan & Patel, 2016, 2017).
Although MLS are more sensitive to cytotoxic agents than other
liposarcoma subtypes, patients with disseminated disease are
usually incurable and chemotherapy is generally administered with
palliative intent, underlining the need for novel, biology-guided
therapeutic options. MLS belong to the group of translocation-
related sarcomas, which are characterized by “quiet” genomes with
few mutations beyond the driving gene fusion. Therefore, counter-
acting the effects of the chimeric FUS-DDIT3 oncoprotein represents,
in principle, the most promising strategy to selectively target MLS
cells. However, transcription factors are notoriously difficult to
inhibit with small molecules, and FUS-DDIT3 has not yet been
shown to be pharmacologically tractable.
In this study, we employed an unbiased functional genomic
approach to search for signaling pathways that are selectively essen-
tial in cells expressing FUS-DDIT3. Large-scale RNA interference
(RNAi) screening identified dependence on YAP1, a transcriptional
co-activator that is physiologically inhibited by the Hippo pathway
responsible for limiting tissue growth and organ size (Pan, 2010), as
specific liability of FUS-DDIT3-expressing MLS cells that could be
exploited for therapeutic benefit.
Results
RNAi screen for essential genes in FUS-DDIT3-expressing
mesenchymal stem cells
To identify genes and/or cellular processes that are essential
specifically in the context of the FUS-DDIT3 fusion gene, we
performed drop-out RNAi screens in two SCP-1 immortalized
human mesenchymal stem cell lines (Bocker et al, 2008; Haasters
et al, 2009) expressing FUS-DDIT3 or empty vector (EV; Fig 1A).
Screens were conducted using Module 1 of the DECIPHER Pooled
Lentiviral Human Genome-Wide shRNA Library, which consists of
approximately 27,500 shRNAs targeting over 5,000 human genes
(Fig 1A, Appendix Fig S1). Candidates for further functional and
mechanistic investigation were selected based on a stepwise
approach. We first integrated the data obtained in SCP-1 cells with
the results of previous DECIPHER screens conducted in cell lines
representing a range of hematopoietic (Burkitt lymphoma, n = 8;
T-cell acute lymphoblastic leukemia, n = 1; acute myeloid
leukemia, n = 4; chronic myeloid leukemia, n = 1) and epithelial
(prostate cancer, n = 4; breast cancer, n = 1; ovarian cancer,
n = 1) malignancies (Appendix Fig S1). Following normalization of
shRNA depletion values using PMAD (Cheung et al, 2011;
preprint: Huellein et al, 2018), we employed RIGER (Luo et al,
2008) to rank genes with respect to FUS-DDIT3-selective essential-
ity and eliminated human core fitness genes identified in genome-
wide CRISPR/Cas9 knockout screens (Shalem et al, 2014; Hart
et al, 2015, 2017; Wang et al, 2015). This approach identified
YAP1, a transcriptional co-activator and central effector of the
Hippo pathway involved in embryonic development, tissue home-
ostasis, and tumorigenesis (Zhao et al, 2011; Harvey et al, 2013),
as lead hit with the highest normalized enrichment score (Fig 1B
and C). The complete dataset obtained from the RNAi screen
conducted in SCP-1 cells is provided as Dataset EV1. To validate
the results of the shRNA screens, SCP-1 cells were lentivirally
transduced with two different RFP-labeled shRNAs targeting YAP1
or NTC shRNA at low transduction efficiency, resulting in mixed
populations of transduced and untransduced cells. Flow cytometric
analysis demonstrated that YAP1 knockdown depleted RFP-positive
cells preferentially in FUS-DDIT3-expressing cultures (Fig 1D,
Appendix Fig S1).
Increased YAP1 activity in MLS cell lines
To translate our findings in genetically engineered SCP-1 cells to
the setting of endogenous FUS-DDIT3 expression, we first deter-
mined YAP1 mRNA and protein levels in a panel of human
liposarcoma cell lines using quantitative RT–PCR and immunoblot-
ting. YAP1 was expressed more strongly in FUS-DDIT3-positive
MLS 402-91, MLS 1765-92, and MLS 1955-91 cells than in cell lines
representing other liposarcoma subtypes (T449 and T778, WDLS;
FU-DDLS-1, DDLS; LiSa-2, PLS) with the exception of SW872 cells
(PLS), which showed similar YAP1 mRNA and protein levels as
MLS 1765-92 and MLS 1955-91 (Fig 2A, Appendix Fig S2A). Frac-
tionation experiments followed by immunoblotting as well as IF
analysis demonstrated that YAP1 was primarily localized in the
nucleus of MLS cells, indicating transcriptional activity, whereas in
SW872 cells the majority of YAP1 protein was retained in the cyto-
plasm (Fig 2B, Appendix Fig S2B). Furthermore, we detected
strong expression of the YAP1 downstream targets FOXM1 and
PLK1 in MLS cell lines (Fig 2C). Together, these observations
demonstrated that cultured human MLS cells exhibit increased
YAP1 activity.
◀ Figure 2. Increased nuclear YAP1 levels in FUS-DDIT3-expressing mesenchymal stem cells, MLS cell lines, and MLS patient samples.A Expression of YAP1 in SCP-1 cells transduced with FUS-DDIT3 or EV and liposarcoma cell lines. One of at least two independent experiments with similar results is
shown. FUS-DDIT3-expressing cell types are indicated in red.
B Expression of YAP1 in cytoplasmic (yellow) and nuclear (blue) fractions from SCP-1 cells transduced with FUS-DDIT3 or EV and liposarcoma cell lines. One of at least
two independent experiments with similar results is shown. FUS-DDIT3-expressing cell types are indicated in red.
C Expression of FOXM1 and PLK1 in MLS cell lines. One of at least two independent experiments with similar results is shown.
D Strong nuclear expression of YAP1, FOXM1, and PLK1 in MLS patient samples (original magnification, ×10 [inset, ×20]).
E Intensity of nuclear YAP1 expression in liposarcoma patient samples. Immunoreactivity was assessed using a semi-quantitative score (0, negative; 1, weak; 2,
moderate; and 3, strong) defining the staining intensity in the positive control (hepatocellular carcinoma) as strong. Only tumors with at least moderate staining
(semi-quantitative score ≥ 2) and ≥ 30% YAP1-positive cells were considered positive for the purposes of the study.
F Proportion of cells with nuclear YAP1 expression in liposarcoma patient samples. Boxes represent mean values and lower and upper quartiles. Whiskers represent
minimum and maximum values.
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Increased YAP1 activity in MLS patient samples
To further explore the involvement of YAP1 in MLS development,
we examined the expression of nuclear YAP1, corresponding to the
transcriptionally active pool, in 223 primary human liposarcoma
specimens (MLS, n = 85; WDLS, n = 55; DDLS, n = 74; PLS, n = 9)
using IHC (Fig 2D–F). Among the MLS specimens, moderate to
strong nuclear YAP1 levels were detected in 90.6% (77/85) of cases,
whereas only 2.4% (2/85) of tumors displayed no YAP1 immunore-
activity; thus, according to the defined criteria, 90.6% of MLS
tumors were positive for YAP1. Accordingly, we detected nuclear
expression of FOXM1 and PLK1. In patients with WDLS, moderate
nuclear YAP1 expression was detected in 41.8% (23/55) of cases,
whereas 16.4% (9/55) of tumors showed no YAP1 staining. For
DDLS, moderate to strong nuclear YAP1 staining was detected in
36.5% (27/74) of cases, while 13.5% (10/74) of specimens showed
no nuclear YAP1 immunoreactivity. Among the PLS specimens,
44.4% (4/9) showed moderate nuclear YAP1 immunoreactivity,
while 22.2% (2/9) of tumors were negative for nuclear YAP1. Nuclear
expression of YAP1 in MLS specimens did not correlate with clinical
characteristics such as patient age, gender, FUS-DDIT3 transcript
variant, or tumor size. These findings provided additional support
that increased YAP1 activity represents a unifying feature in MLS.
Requirement for YAP1 activity in MLS cell lines
To confirm the differential requirement for YAP1 identified by RNAi
screen, we suppressed YAP1 expression in seven human liposar-
coma cell lines using two different shRNAs. YAP1 knockdown
depleted FUS-DDIT3-expressing MLS 402-91 and MLS 1765-92 cells
to a similar extent as knockdown of KIF11, an essential cell cycle
regulator that served as positive control, whereas there was little
effect in cell lines representing other liposarcoma subtypes (Fig 3A
and B, Appendix Fig S3A and B). To further ensure the specificity of
these results, we performed rescue experiments with a shRNA target-
ing the 30 untranslated region (UTR) of YAP1 mRNA. We first trans-
duced FUS-DDIT3-positive MLS 1765-92 cells with EV or the YAP1
coding sequence, which lacks the 30 UTR. Subsequent knockdown of
endogenous YAP1 inhibited the growth of EV-transduced cells,
whereas the RNAi-induced phenotype was countered by expression
of the shRNA-resistant YAP1 cDNA (Fig 3C and D). In a
complementary approach, we observed that siRNA-mediated tran-
sient knockdown of YAP1 also reduced the viability and proliferation
of MLS cells, which was accompanied by decreased YAP1 target gene
expression (Fig 3E). Together, these data indicated that FUS-DDIT3-
positive human MLS cells are dependent on YAP1 activity.
Proliferation arrest, senescence, and apoptosis by YAP1
suppression in MLS cells
To examine the functional basis for the depletion of FUS-DDIT3-
expressing cells upon YAP1 suppression, we first analyzed the cell
cycle profiles of MLS 402-91 and MLS 1765-92 cells 5 days after
shRNA knockdown of YAP1. Flow cytometric analysis of EdU incor-
poration demonstrated that YAP1 knockdown cells accumulated in
the G1 phase of the cell cycle, whereas cells transduced with NTC
shRNA were unaffected (Fig 3F, Appendix Fig S3C). In addition,
YAP1 knockdown resulted in a senescence-like phenotype, as
evidenced by increased senescence-associated b-galactosidase activ-
ity (Fig 3G), loss of RB1 phosphorylation, and induction of CDKN1A
(also known as p21cip1) expression (Fig 3H). Finally, we observed
that YAP1 suppression significantly increased apoptosis, as assessed
by detection of caspase-3/8 and poly (ADPribose) polymerase
(PARP) cleavage (Fig 3I).
Causal relationship between FUS-DDIT3 expression and increased
YAP1 activity
Our observations suggested a causal relationship between the pres-
ence of FUS-DDIT3 and increased YAP1 activity. Consistent with
this hypothesis, stable expression of FUS-DDIT3 in SCP-1 cells
increased YAP1 mRNA levels approximately threefold compared to
EV-transduced control cells (Appendix Fig S2A), which was paral-
leled by elevated total and nuclear YAP1 protein expression (Fig 2A
and B). FUS-DDIT3 induced the expression and nuclear localization
of YAP1 downstream effectors such as FOXM1 and PLK1 (Fig 4A
and B). Furthermore, TEAD luciferase reporter assays employing
the 8xGTIIC system demonstrated that expression of FUS-DDIT3
significantly increased YAP1-responsive luciferase activity compared
to the backbone vector control (Fig 4C). Together, these findings
supported a role for FUS-DDIT3 in establishing increased YAP1
activity in human MLS cells.
◀ Figure 3. Requirement for YAP1 activity in MLS cell lines.A Competition assays with liposarcoma cell lines transduced with RFP-labeled NTC or YAP1 shRNAs. Flow cytometric quantification of RFP-positive cells on day 17
relative to day 3 showed that YAP1 knockdown was preferentially toxic to MLS cells. Bars and error bars represent the mean  SD of two independent experiments.
B Aggregate data from competition assays shown in (A). Statistical significance was assessed using an unpaired t-test. LS, non-myxoid liposarcoma.
C Competition assays with MLS 1765-92 cells transduced with an RFP-labeled NTC shRNA or an RFP-labeled shRNA against the YAP1 30UTR following transduction with
EV or the YAP1 coding sequence. Flow cytometric quantification of RFP-positive cells on day 17 relative to day 3 showed that cell viability was rescued by expression
of the shRNA-resistant YAP1 cDNA. Bars and error bars represent the mean  SD of two independent experiments.
D Expression of total and exogenous V5-tagged YAP1 in MLS 1765-92 cells shown in (C). One of at least two independent experiments with similar results is shown.
E Cell viability and expression of FOXM1 and PLK1 in MLS cell lines following siRNA-mediated YAP1 knockdown. Bars and error bars represent the mean  SD of three
independent experiments, unpaired t-test. The blots represent one of at least three independent experiments with similar results.
F Flow cytometric cell cycle analysis of MLS cell lines following shRNA-mediated YAP1 knockdown. Bars and error bars represent the mean  SD of three independent
experiments, two-way ANOVA; ns, not significant.
G Senescence-associated b-galactosidase (SABG) staining intensity in MLS cell lines following shRNA-mediated YAP1 knockdown. Bars and error bars represent the
mean  SD of ten random microscopic fields, two-way ANOVA.
H Expression of CDKN1A, CDKN2A, total and phosphorylated RB1, and TP53 in MLS cell lines following shRNA-mediated YAP1 knockdown. One of at least two
independent experiments with similar results is shown.
I Expression of cleaved PARP and cleaved caspase-3/8 in MLS cell lines following shRNA-mediated YAP1 knockdown. One of at least two independent experiments with
similar results is shown.
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Figure 4. Causal relationship between FUS-DDIT3 expression and increased YAP1 activity.
A Expression of YAP1 and downstream effectors in SCP-1 cells transduced with FUS-DDIT3 or EV. One of at least three independent experiments with similar results is
shown.
B Expression of YAP1 and downstream effectors in cytoplasmic (yellow) and nuclear (blue) fractions from SCP-1 cells transduced with FUS-DDIT3 or EV. One of at least
two independent experiments with similar results is shown.
C YAP1-responsive luciferase activity in SCP-1 cells transduced with FUS-DDIT3. Relative luciferase activity is displayed as fold change relative to control. Bars and error
bars represent the mean  SD of three independent experiments, unpaired t-test.
D Localization of FUS-DDIT3 and YAP1 in MLS 1765-92. Nuclei were counterstained with DAPI. The original magnification was ×63, and images were zoomed in four
times for co-localization analysis. The correlation between red and green fluorescence was determined by Pearson coefficient analysis (square, area for signal
acquisition).
E Co-IP of transiently expressed FUS-DDIT3 and YAP1 from HEK293T cells. V5-tagged YAP1 was pulled down using an anti-V5 antibody, and interacting proteins were
detected by immunoblotting. One of at least two independent experiments with similar results is shown.
F Co-IP of endogenous FUS-DDIT3 and YAP1 from MLS 1765-92 cells. FUS-DDIT3 was pulled down using an anti-DDIT3 antibody, and interacting proteins were detected
by immunoblotting. One of at least two independent experiments with similar results is shown.
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Given the role of FUS-DDIT3 in deregulation of YAP1 expression
and the predominant nuclear localization of YAP1 in MLS cells, we
hypothesized that these proteins may interact to coordinately estab-
lish a gene expression program that promotes MLS development. In
support of this concept, immunofluorescence demonstrated that
FUS-DDIT3 and YAP1 co-localize in the nucleus of MLS 1765-92 and
MLS 402-91 cells (Fig 4D, Appendix Fig S4), and their direct physi-
cal association was verified by co-IP of transiently expressed or
endogenous proteins from HEK293T and MLS 1765-92 cells, respec-
tively (Fig 4E and F).
Sensitivity of MLS cells to pharmacologic inhibition of
YAP1 activity
Our genetic data suggested that aberrant YAP1 activity might be a
therapeutic target in MLS. We therefore evaluated the growth of MLS
cells in the presence of verteporfin, a second-generation photosensi-
tizer approved for the treatment of age-related macular degeneration
that inhibits YAP1 signaling by disrupting the YAP1-TEAD complex
and augmenting its sequestration in the cytoplasm (Liu-Chittenden
et al, 2012; Brodowska et al, 2014; Wang et al, 2016). These experi-
ments showed that verteporfin suppressed the viability and prolifera-
tion of all three MLS cell lines analyzed in a dose-dependent manner
(Fig 5A, Table 1). The growth-inhibitory effects of verteporfin could
be attributed to increased apoptosis and a significant reduction in
mitotic activity, as assessed by flow cytometric quantification of
cleaved PARP and phosphorylated histone H3S10, respectively
(Fig 5B, Table 2), and were accompanied by reciprocal dose-depen-
dent changes in the expression of the YAP1 downstream effectors
FOXM1 and PLK1 (Fig 5C) (Eisinger-Mathason et al, 2015; Fullen-
kamp et al, 2016). Finally, TEAD reporter assays demonstrated that
verteporfin significantly decreased luciferase activity in MLS cell
lines co-transfected with a constitutively active YAP1S127A mutant
(Fig 5D). Collectively, these data showed that MLS cells are sensitive
to pharmacologic blockade of YAP1 activity, indicating that their
overreliance on YAP1 may provide a therapeutic opportunity.
In vivo efficacy of YAP1 inhibition against MLS xenografts
To verify the effect of YAP1 inhibition on MLS growth in vivo, we
deposited MLS 402-91 and MLS 1765-92 cells transduced with two
different shRNAs targeting YAP1 on the surface of chicken CAM and
observed that YAP1 knockdown significantly impaired their tumor-
forming capacity (Fig 5E). In addition, topical administration of
verteporfin to established MLS 402-91 and MLS 1765-92 xenografts
resulted in a significant reduction of tumor volume compared to the
vehicle-treated control group (Fig 5F). Collectively, these data
showed that YAP1 inhibition impairs the initiation and maintenance
of MLS tumors in vivo, further supporting the idea that overactive
YAP1 signaling could represent a new target for therapeutic inter-
vention in patients with FUS-DDIT3-driven MLS.
Discussion
MLS is a lipogenic malignancy with propensity to local relapse and
distant metastasis. High histological grade, defined as round cell
component > 5%, serves as a major predictor of unfavorable
clinical outcome (Smith et al, 1996; Antonescu et al, 2001).
Although high-grade MLS are more sensitive to conventional radio-
and chemotherapy than other liposarcoma subtypes, prognosis in
the metastatic situation is poor (Ratan & Patel, 2016). The
chimeric FUS-DDIT3 fusion protein, a hallmark of MLS, acts as an
aberrant transcription factor and has been shown to drive MLS
development in mice (Kuroda et al, 1997; Riggi et al, 2006).
Though FUS-DDIT3 has been documented to be incorporated into
transcription complexes and to be associated with chromatin
remodeling (Goransson et al, 2009), its specific mode of action
remains incompletely understood. As other translocation-related
sarcomas, e.g., Ewing sarcoma, synovial sarcoma, or alveolar
rhabdomyosarcoma, MLS genomes harbor few somatic mutations,
underscoring the dominant role of FUS-DDIT3 in MLS pathogenesis
(Barretina et al, 2010; Crompton et al, 2014; Shern et al, 2014;
Tirode et al, 2014; Trautmann et al, 2019). Since therapeutic inhi-
bition of the chimeric fusion protein itself represents a challenge,
it appears most promising to intercept signaling pathways that are
functionally dependent on FUS-DDIT3 activity for selective target-
ing of MLS cells.
In this study, we employed an unbiased functional genomic
approach to uncover that human mesenchymal stem cells engi-
neered to express FUS-DDIT3 require YAP1, a transcriptional co-
activator and central effector of the Hippo signal transduction
pathway (Pan, 2010). The essential role of YAP1 in different
epithelial malignancies is well established (Harvey et al, 2013);
however, evidence implicating YAP1 in mesenchymal tumori-
genesis is sparse (Crose et al, 2014; Tremblay et al, 2014;
Eisinger-Mathason et al, 2015; Fullenkamp et al, 2016; Cancer
Genome Atlas Research Network, 2017). To verify the require-
ment for YAP1 in the context of endogenous FUS-DDIT3 expres-
sion, we analyzed the prevalence and functional relevance of
YAP1 in a representative panel of human liposarcoma cell lines
and a large cohort of MLS tumor specimens. Expectedly, YAP1
positivity was not restricted to MLS; however, nuclear expression
of YAP1 was significantly more prevalent in MLS compared to
other liposarcomas, and YAP1-positive tumors showed strong
expression of the YAP1 downstream targets FOXM1 and PLK1.
These findings are in line with a previous immunohistochemical
study (Fullenkamp et al, 2016) and provide evidence that
increased YAP1-mediated transcriptional activity represents an
essential feature of MLS. Accordingly, RNAi-based YAP1 depletion
in MLS cells resulted in suppression of cell viability, cell
cycle arrest, cellular senescence, and induction of apoptosis,
accompanied by decreased YAP1 target gene expression.
Our observations in mesenchymal stem cells and MLS cell lines
imply a functional link between FUS-DDIT3 expression and aberrant
YAP1 activity, thereby providing new insights into the oncogenic
properties of FUS-DDIT3. In addition to the induction of YAP1 tran-
scription by FUS-DDIT3, our data also indicate a direct physical
interaction between the FUS-DDIT3 and YAP1 proteins, which might
point to the coordinate establishment of gene expression programs
that promote MLS tumorigenesis. Given the contextual requirement
for YAP1 activity, a YAP1-directed therapeutic approach could
represent a rational strategy to selectively target FUS-DDIT3-expres-
sing MLS cells. Consistent with this hypothesis, RNAi-mediated
depletion of YAP1 or pharmacologic inhibition of the YAP1-TEAD
transcriptional complex with verteporfin (Liu-Chittenden et al,
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2012) suppressed cell viability and YAP1 target gene expression in
MLS cells. The growth-suppressive effects of YAP1 knockdown or
verteporfin treatment could be recapitulated in MLS cell line-based
xenograft models in vivo. Given recent reports that imbalances in
proteostasis and subsequent proteotoxicity may also contribute to
the anti-neoplastic activity of verteporfin (Zhang et al, 2015), the
A
C
D
F
E
B
Figure 5.
ª 2019 The Authors EMBO Molecular Medicine 11: e9889 | 2019 9 of 15
Marcel Trautmann et al YAP1 signaling in myxoid liposarcoma EMBO Molecular Medicine
pharmacologic assays need to be interpreted with caution. However,
in light of the additional evidence gained from multiple RNAi
approaches, we are confident that the effects of verteporfin observed
in MLS cells are predominantly due to the inhibition of YAP1-TEAD
complexes. Collectively, our data identify YAP1 as a major down-
stream effector of FUS-DDIT3 in MLS development and document
its potential as a novel target for therapeutic intervention.
While YAP1 represents a new player in MLS pathogenesis, alter-
ations of various Hippo signaling intermediates have recently been
found in other sarcoma subtypes. A large-scale genomic study
described YAP1 copy number variations to occur at low frequencies
in DDLS and undifferentiated pleomorphic sarcoma/myxofibrosar-
coma (Helias-Rodzewicz et al, 2010; Cancer Genome Atlas Research
Network, 2017). Furthermore, Eisinger-Mathason and colleagues
queried the same dataset to identify copy number losses of LATS2
and SAV1, effectors of the Hippo signaling cascade that are essential
for negative regulation of YAP1 (Eisinger-Mathason et al, 2015).
Beyond that, aberrant Hippo signaling can arise from chromosomal
translocations involving YAP1 or WWTR1 (encoding TAZ) as in
epithelioid hemangioendothelioma, another fusion gene-driven
soft-tissue tumor (Errani et al, 2011; Tanas et al, 2011, 2016;
Antonescu et al, 2013). These findings point to a major role of
aberrant Hippo signals in different soft-tissue malignancies, which
may previously have been underestimated. In MLS, however,
genomic alterations affecting the Hippo pathway have not been
described (Barretina et al, 2010). Thus, overactive YAP1 signaling in
MLS appears to be exclusively mediated by FUS-DDIT3. This insight
highlights the potential of functional screening to identify essential
genes that evade detection by other genomic technologies and is
reminiscent of the situation in alveolar rhabdomyosarcoma, another
fusion-driven soft-tissue tumor in which the pathognomonic
PAX3-FOXO1 oncoprotein promotes tumorigenesis by dysregulation
of YAP1 (Crose et al, 2014). These two entities may therefore define
a biologically distinct subgroup of soft-tissue sarcomas in which
aberrant YAP1/Hippo signaling is activated by chimeric transcription
factors.
We previously described a related and potentially targetable
oncogenic mechanism in MLS that involves activation of the IGF1R-
PI3K-AKT signaling cascade through FUS-DDIT3-dependent induc-
tion of IGF2 transcription (Trautmann et al, 2017). Since there is
convincing evidence for simultaneous activation of multiple signal-
ing pathways in MLS pathogenesis, future therapeutic concepts need
to be focused on an integrated signaling network concept. In this
context, comprehensive molecular diagnostic approaches will be
key to assign MLS patients to molecularly stratified clinical trials
based on the identification of appropriate predictive biomarkers.
The data presented here indicate that immunohistochemical screen-
ing for nuclear YAP1 could provide such a biomarker, which should
be prospectively addressed in future studies.
In conclusion, we have identified dependence on aberrant YAP1
activity as specific liability of FUS-DDIT3-expressing MLS cells, and
provide preclinical evidence that YAP1-mediated signal transduction
represents a candidate target for therapeutic intervention that
warrants further investigation.
Materials and Methods
Cell culture
The MLS cell lines MLS 402-91, MLS 1955-91 (FUS-DDIT3 type 1),
MLS 1765-92 (type 8), and MLS 2645-94 (type 2) (all contributed by
Pierre A˚man) and the liposarcoma cell lines T449, T778 (well-
differentiated liposarcoma [WDLS], both kindly provided by Florence
Pedeutour), SW872 (obtained from CLS Cell Lines Service), LiSa-2
(pleomorphic liposarcoma [PLS], kindly provided by Silke Bru¨derlein
and Peter Mo¨ller), and FU-DDLS-1 (dedifferentiated liposarcoma
Table 1. IC50 values for verteporfin in MLS cell lines.
Compound
IC50 (lM)
MLS 402-91
(type 1)
MLS 1765-92
(type 8)
MLS 2645-94
(type 2)
Verteporfin 0.62  0.15 0.69  0.10 0.82  0.06
Values were calculated by non-linear regression analysis. Results are
represented as the mean  SEM of at least three independent experiments.
Table 2. Fold changes in apoptotic and mitotic fractions of MLS cell
lines upon verteporfin treatment.
Cell line
Cleaved PARP
(D214)
Phosphorylated
histone H3 (S10)
MLS 402-91 (type 1) 11.58  0.23 0.36  0.01
MLS 1765-92 (type 8) 4.00  0.17 0.42  0.02
MLS 2645-94 (type 2) 1.72  0.09 0.13  0.03
Results are represented as the mean  SEM of at least three independent
experiments.
◀ Figure 5. Sensitivity of MLS cell lines to pharmacologic YAP1 inhibition.A Viability and proliferation of MLS 402-91, MLS 1765-92, and MLS 2645-94 cells cultured in the presence of verteporfin. Data points and error bars represent the
mean  SEM of one representative experiment performed in quintuplicate.
B Flow cytometric analysis of apoptosis (cleaved PARP) and mitotic fraction (phosphorylated histone H3S10) in MLS cell lines cultured in the presence of 0.25 lM
verteporfin. One of two independent experiments with similar results is shown.
C Expression of total YAP1 and downstream effectors (FOXM1 and PLK1) in MLS cell lines treated with 0.5 or 1 lM verteporfin for 15 h. One of at least three
independent experiments with similar results is shown.
D YAP1-responsive luciferase activity in MLS cell lines transfected with a constitutively active YAP1S127A mutant and treated with 1 lM verteporfin. Relative luciferase
activity is displayed relative to control. Bars and error bars represent the mean  SD of three independent experiments, unpaired t-test.
E Tumor formation on chicken CAM of MLS cell lines following shRNA-mediated YAP1 knockdown. The number of tumors is given above each bar, Fisher exact test; ns,
not significant.
F Tumor growth on chicken CAM of MLS cell lines following treatment with 1 lM verteporfin. Shown are tumor volumes and representative photographs of tumors.
Bars and error bars represent the mean  SEM of at least four tumors, unpaired t-test.
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[DDLS], kindly provided by Jun Nishio) were cultured in RPMI-1640
supplemented with 10% fetal bovine serum (FBS; Biochrom) and 1%
penicillin/streptomycin (P/S; Biochrom). The flasks for culturing
MLS 1955-91 were additionally coated with 10% Collagen R solution
(Serva). HEK293T cells were kindly provided byWilliam C. Hahn and
grown in DMEM (10% FBS, 1% P/S). The SCP-1 cell system (Bocker
et al, 2008; Haasters et al, 2009) was established by Thomas Kindler
and cultured in MEM (10% FBS, 1% P/S). Cells were grown under
standard conditions (37°C, humidified atmosphere, 5% CO2) and
routinely tested for mycoplasma contamination. Cell line identity and
purity were verified using the Multiplex Cell Authentification and
Contamination Tests (Multiplexion) and/or by documentation of the
specific gene fusions. To study the effects of verteporfin (Targetmol
dissolved in DMSO [Sigma-Aldrich]), MLS cells were grown in RPMI-
1640 with 2% FBS. The final DMSO concentration did not exceed
0.2% for all in vitro and in vivo applications.
Vectors and lentiviral transduction
The YAP1 and FUS-DDIT3 cDNA were amplified from MLS 402-91
cells. YAP1 and FUS-DDIT3 cDNAs were cloned into pLenti6.2/V5-
DEST and pLenti7.3/V5-DEST lentiviral expression vectors, respec-
tively, using Gateway Technology (Invitrogen). Short hairpin RNA
(shRNA) sequences were taken from the DECIPHER Pooled Lentivi-
ral Human Genome-Wide shRNA Library (Cellecta) and cloned into
the BbsI site of the pRSI12-U6-sh-UbiC-TagRFP-2A-Puro or pRSI9-
U6-sh-UbiC-TagRFP-2A-Puro lentiviral vectors (Cellecta). shRNA
target sequences were as follows: shYAP1-2: 50-CCC AGT TAA ATG
TTC ACC AAT-30, shYAP1-3: 50-CAG GTG ATA CTA TCA ACC AA
A-30, shKIF11: 50-GCG TAC AAG AAC ATC TAT AAT-30, shEIF3A:
50-GCG CCT TGA GAG TCT GAA TAT-30, and shNTC (non-targeting
control): 50-CAA CAA GAT GAA GAG CAC CAA-30. Generation of
viral supernatants and viral transduction was performed as previ-
ously described (Scholl et al, 2009). Cells were selected with 10 lg/
ml blasticidin (Life Technologies) or 2 lg/ml puromycin (Sigma-
Aldrich). GFP-positive SCP-1 cells, either transduced with pLen-
ti7.3/V5-DEST-FUS-DDIT3 or empty vector control, were isolated by
means of fluorescent activating cell sorting.
Short hairpin RNA screening and data analysis
Screens were performed in duplicates using Module 1 of the DECI-
PHER Pooled Lentiviral Human Genome-Wide shRNA Library (Cel-
lecta), which consists of 27,500 shRNAs targeting 5,043 human genes
(preprint: Huellein et al, 2018). SCP-1 cells (3.4 × 107) stably trans-
duced with either FUS-DDIT3 or an empty control vector (EV) were
transduced with library virus at a multiplicity of infection of 0.7 in the
presence of 5 lg/ml polybrene (Millipore). After 3 days, half of the
cells were harvested as baseline sample and the other half of the cells
were selected with 2 lg/ml puromycin for 3 days, cultured without
puromycin for six additional days, and harvested as drop-out sample.
Baseline and drop-out samples were subjected to genomic DNA
extraction and PCR amplification of barcode regions for high-
throughput sequencing as described previously (Słabicki et al, 2016).
Raw sequencing data were processed using the DECIPHER Bar-
Code Deconvoluter software (Cellecta) for converting read counts of
barcode sequences to shRNA read counts. The read counts of indi-
vidual shRNAs were normalized to the mean of total read counts,
and the log2 fold change (LFC) was calculated for each cell line by
dividing the normalized read counts of the drop-out sample by those
of the baseline sample followed by log2 transformation. LFC values
were processed with the GenePattern module “NormLines” using
the peak median absolute deviation method (PMAD) (Cheung et al,
2011), resulting in rescaled LFC values with similar ranges in all cell
lines to obtain comparability. Finally, PMAD normalized values
were analyzed by RNAi Gene Enrichment Ranking (RIGER) (Luo
et al, 2008) to calculate differential gene effects between FUS-
DDIT3-expressing SCP-1 cells and other cell lines.
Short interfering RNA-mediated knockdown
MLS 402-91 and MLS 1765-92 cells were grown in medium supple-
mented with 2% FBS to a density of 50%, transfected with 25 pmol
of pre-validated short interfering RNA (siRNA) targeting YAP1 (50-
GGA AGG AGA UGG AAU GAA CAU AGA A-30; Life Technologies,
Assay Identifier HSS115944) or a non-targeting control siRNA
(BLOCK-iT Alexa Fluor Red Fluorescent Control, Life Technologies)
using Lipofectamine RNAiMAX (Life Technologies), and harvested
for immunoblotting after 72 h.
RNA isolation, cDNA synthesis, and quantitative RT–PCR
Total RNA was isolated using the RNeasy Plus Mini Kit (Qiagen)
and reverse-transcribed using the High-Capacity cDNA Reverse
Transcription Kit (Applied Biosystems). Quantitative RT–PCR was
performed on a LightCycler 480 instrument (Roche) using 0.1–
100 ng cDNA, 10 lM primers, and LightCycler 480 SYBR Green I
Master reagents (Roche) in a total volume of 10 ll. Target gene
expression was calculated based on the DDCt method and normal-
ized to ACTB and GAPDH as reference genes. Primer sequences are
given in Appendix Table S1.
Tumor specimens and tissue microarrays
Tissue microarrays (TMAs) were prepared from 223 formalin-fixed,
paraffin-embedded (with two representative 1-mm cores) liposar-
coma specimens (MLS, n = 85; WDLS, n = 55; DDLS, n = 74; PLS,
n = 9) selected from the archive of the Gerhard-Domagk-Institute of
Pathology (Mu¨nster, Germany). Diagnoses were reviewed by two
experienced pathologists based on current World Health Organiza-
tion criteria. From each tumor, two areas were selected by two expe-
rienced pathologists to account for potential heterogeneity, e.g.,
with regard to the round cell content of MLS, and occasional necro-
biotic areas and their neighborhood were excluded from TMA
sampling. The study was approved by the Ethics Review Board of
the University of Mu¨nster (2015-548-f-S), and experiments were
conformed to the principles set out in the World Medical Associa-
tion Declaration of Helsinki and the United States Department of
Health and Human Services Belmont Report. Written informed
consent from patients was not requested by the Ethics Review Board
of the University of Mu¨nster (2015-548-f-S).
Cell viability and proliferation assays
For RFP competition assays, cells were transduced with lentiviral
shRNAs at an efficiency of approximately 50%. The proportion of
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RFP-positive cells was measured by flow cytometry on a BD LSR II
instrument (BD Biosciences) after 3 days (baseline) and every 2–
3 days thereafter. To determine the effects of drug treatment, 2.5 × 103
MLS cells were seeded in 96-well plates and exposed to increasing
concentrations of verteporfin for 72 h. Cell viability and proliferation
were measured using the Cell Proliferation Kit I (MTT) (Roche) as
previously described (Michels et al, 2013; Trautmann et al, 2014).
Immunohistochemistry
Immunohistochemistry (IHC) was performed with a BenchMark
ULTRA Autostainer (VENTANA/Roche) on 3-lm TMA sections. The
staining procedure included heat-induced (95-100°C) epitope
retrieval using Tris-Borate-EDTA buffer (pH 8.4) for 32-72 min,
incubation with primary antibodies for 16–120 min, and signal
detection using the OptiView DAB IHC Detection Kit (VENTANA/
Roche). The following primary antibodies were used: YAP (mono-
clonal rabbit, D8H1X, 1:100, #14074, Cell Signaling), FOXM1 (mon-
oclonal mouse, G-5, 1:1000, #376471, Santa Cruz), PLK1
(monoclonal rabbit, 208G4, 1:25, #4513, Cell Signaling). Immunore-
activity was assessed using a semi-quantitative score (0, negative; 1,
weak; 2, moderate; and 3, strong) defining the staining intensity in
the positive control (hepatocellular carcinoma) as strong. Negative
control stainings using an appropriate IgG subtype (DCS) were
included. Only tumors with at least moderate staining (semi-quanti-
tative score ≥ 2) and ≥ 30% (YAP1 and FOXM1) or ≥ 5% (PLK1)
positive cells were considered positive for the purposes of the study.
The IHC readers were blinded to outcome data, and the score cut
point (positive = semi-quantitative score ≥ 2) was pre-specified
without prior analyses of the clinical course.
Immunofluorescence
Cells were grown on poly-L-lysine-coated chamber slides (Sigma-
Aldrich) or collagen-coated coverslips (Corning), fixed in 4%
paraformaldehyde (PFA), permeabilized and blocked with 5% BSA
or 2% goat serum and 0.3-3% Triton X-100, and incubated with
primary antibodies (YAP, monoclonal rabbit, D8H1X, 1:100,
#14074, Cell Signaling; CHOP/DDIT3, monoclonal mouse, #2895,
Cell Signaling, 1:1,000) at 4°C over night. After secondary antibody
incubation (Life Technologies, 1:1,000), cells were mounted in
Vectashield Mounting Medium with DAPI (Vector Laboratories) or
ProLong Gold Antifade Reagent with DAPI (Cell Signaling).
Immunofluorescence (IF) analysis was performed with a Leica
DM5500 B microscope or a Leica TCS SP5 confocal microscope. Co-
localization analysis was performed using Fiji software plugins
“Colocalization Finder” and “Image Correlator” to obtain correlation
plots and calculate Pearson correlation coefficients (Schindelin et al,
2012).
Immunoblotting
Cytoplasmic and nuclear fractions were prepared from cell pellets
with 0.1% NP-40 lysis buffer (0.1% NP-40 [BioVision] and Halt
Protease and Phosphatase Inhibitor Cocktail [Thermo Fischer, 1:100]
in Dulbecco’s phosphate-buffered saline [DPBS]) to obtain the cyto-
plasmic fraction, followed by nuclear lysis with RIPA buffer (50 mM
Tris–HCl, 150 mM NaCl, 0.1% SDS, 0.5% sodium deoxycholate, 1%
Triton X-100, Halt Protease and Phosphatase Inhibitor Cocktail
[1:100]) to obtain the nuclear fraction. Whole-cell lysates were
prepared with Triton X-100 lysis buffer (20 mM Tris–HCl, 150 mM
NaCl, 1 mM EDTA, 10% Glycerol, 1% Triton X-100, Halt Protease
and Phosphatase Inhibitor Cocktail [1:100]). Protein extracts (10–
50 lg) were subjected to SDS–PAGE and transferred to PVDF
membranes (Carl Roth). Membranes were blocked with 5% dry milk
in TBST, followed by incubation with primary and HRP-linked
secondary antibodies. Chemiluminescent signals were detected by
autoradiography or the Molecular Imager ChemiDoc System (Bio-
Rad). Signal intensities were quantified using Fiji software (Schin-
delin et al, 2012). Antibodies are given in Appendix Table S2.
Immunoprecipitation
HEK293T cells were transfected with YAP1 and FUS-DDIT3 expres-
sion plasmids (pLenti6.2/V5-DEST and pLenti7.3/V5-DEST, respec-
tively) and lysed with Triton X-100 lysis buffer after 40 h. Protein
lysates (500 lg) were incubated with 30 ll SureBeads Protein
G Magnetic Beads (Bio-Rad) and 1 ll V5 Tag Monoclonal Antibody
(Invitrogen) in a total volume of 200 ll. MLS 1765-92 cells were
washed twice with 0.1% NP-40 lysis buffer to remove the cytoplasm,
and nuclei were resuspended in HEPES lysis buffer (25 mM HEPES,
100 mM NaCl, 1 mM EDTA, 0.5% Triton X-100, Halt Protease and
Phosphatase Inhibitor Cocktail [1:100]) and sonicated using a
Diagenode Bioruptor device. After centrifugation, protein super-
natants (750 lg) were incubated with 30 ll SureBeads Protein G
Magnetic Beads and 4 ll YAP antibody (#14074, Cell Signaling, 1:50)
or 4 ll DDIT3 antibody (#2895, Cell Signaling, 1:50) in a total volume
of 200 ll, and 1 lg rabbit IgG (sc-2027, Santa Cruz) and 1 lg mouse
IgG2a (554126, BD Biosciences) served as controls. Beads were
washed and subjected to immunoblotting on the next day.
Luciferase assays
To assess YAP1-mediated transcriptional activity, MLS cells were
transfected with TEAD (8xGTIIC) luciferase reporter plasmid
(Dupont et al, 2011). For extrinsic activation of YAP1, MLS cells
were co-transfected with a constitutively active YAP1S127A mutant
(Zhao et al, 2007). The amount of plasmid DNA in each transfection
was kept constant by addition of the non-coding plasmid backbone.
Reporter assays were performed in triplicates using the Dual-Luci-
ferase Reporter Assay System (Promega) after 24 h. Firefly luci-
ferase activity was normalized to a co-transfected Renilla pRL-TK
control plasmid (Promega) to account for differences in transfection
efficiency. For verteporfin treatment, medium containing transfec-
tion reagent was replaced after 6 h with medium containing 1 lM
verteporfin and 2% FBS.
Cell cycle and apoptosis analysis
Cell cycle analysis was performed with the Click-iT Plus EdU Flow
Cytometry Assay Kit (Invitrogen) and DAPI as DNA staining reagent
(BD Biosciences). Five days after shRNA transduction, cells were
incubated with 10 lM EdU solution for 1 h, washed with 3 ml 1%
BSA/DPBS, fixed with 4% PFA, permeabilized, and incubated with
EdU detection solution and DAPI. Stained cells were acquired on a
BD LSR II flow cytometer (BD Biosciences) within 1 h.
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The effects of verteporfin on apoptotic and mitotic rates were
assessed by flow cytometric detection of cleaved PARP and phos-
phorylated histone H3S10, respectively. MLS cells grown in medium
supplemented with 2% FBS were treated with 0.25 lM verteporfin
for 72 h, detached using 0.025% trypsin (Life Technologies), fixed
in 2% PFA, washed in PBS, and permeabilized in 0.25% Triton X-
100/PBS for 5 min on ice. After an additional washing step, cells
were stained for 60 min with PE Mouse anti-Cleaved PARP
(Asp214) (BD Biosciences) and phospho-Histone H3S10 (#9716,
Alexa Fluor 647 Conjugate, Cell Signaling) antibodies. Fluorescence
intensity was measured using a FACSCanto II flow cytometer, and
data were analyzed using the FACSDiva software (BD Biosciences).
Senescence assays
Five days after shRNA transduction, cells were fixed with 4% PFA
and stained with the Senescence b-Galactosidase Staining Kit (Cell
Signaling). Images of 10 random fields per sample were taken with
a Zeiss Cell Observer microscope at ×100 magnification. The stain-
ing intensity of senescent cells was determined using Fiji software
(Schindelin et al, 2012). Normalized staining intensities were calcu-
lated dividing the total intensity by the number of b-galactosidase-
positive cells.
Chicken chorioallantoic membrane assays
MLS 402-91 and MLS 1765-92 cells were transduced with lentiviral
shRNAs, selected with 2 lg/ml puromycin for 2 days, and after four
additional days, 1.5 × 106 cells were deposited within 5-mm silicon
rings on the surface of chicken chorioallantoic membranes (CAM)
8 days postfertilization. Images were acquired after 4 days of incu-
bation, and tumor areas were calculated using Fiji software and
normalized to the area of the silicon ring.
For drug treatment, CAM assays were performed as previously
described (Syrovets et al, 2005). In brief, 1 × 106 MLS 402-91 and
MLS 1765-92 cells in medium and Matrigel (1:1) were xenografted
onto chicken CAM (within 5-mm silicon rings), and 1 lM verte-
porfin or vehicle (0.2% DMSO in NaCl 0.9%) was applied topically
on days 8 and 9. Three days after treatment initiation, xenografts
were explanted, fixed in 5% PFA, and processed for histopathologi-
cal examination. Tumor volume (mm3) was calculated according
to the formula: length (mm) × width2 (mm) × p/6 (Tomayko &
Reynolds, 1989).
Statistical analysis
Statistical analysis was performed using paired or unpaired two-
tailed t-test, two-way ANOVA, or Fisher exact test as appropriate.
P-values < 0.05 were considered significant. Computations were
performed using GraphPad Prism (GraphPad Software).
Expanded View for this article is available online.
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The paper explained
Problem
Myxoid liposarcoma (MLS) is an aggressive mesenchymal malignancy
with few therapeutic options. Most MLS are driven by the FUS-DDIT3
fusion gene. However, the mechanisms underlying MLS development,
including clinically actionable genetic vulnerabilities, are incompletely
understood.
Results
Pooled RNA interference (RNAi) screening uncovered context-depen-
dent essentiality of YAP1, encoding a transcriptional co-activator, in
FUS-DDIT3-expressing mesenchymal stem cells. Immunohistochem-
istry analysis of MLS patient specimens revealed that nuclear YAP1
expression is significantly more prevalent in MLS compared to other
liposarcoma subtypes. YAP1 depletion in MLS cell lines caused
suppression of cell viability, cell cycle arrest, cellular senescence, and
induction of apoptosis accompanied by decreased YAP1 target gene
expression, and primary MLS tumors showed strong expression of
YAP1 downstream effectors. Mechanistically, FUS-DDIT3 promoted
YAP1 transcription, nuclear localization, and transcriptional activity
and physically associated with YAP1 in the nucleus of MLS cells. Phar-
macologic inhibition of YAP1 activity with verteporfin suppressed cell
viability and YAP1 target gene expression in MLS cell lines, and the
growth-inhibitory effects of YAP1 knockdown or verteporfin treatment
could be recapitulated in MLS cell line-based xenograft models.
Impact
These findings provide insight into the functional underpinnings of
MLS development. More broadly, the data underscore the potential of
functional screens for uncovering vulnerabilities in cancers with low
mutational burden, such as translocation-related sarcomas, whose
critical dependencies evade detection by DNA and RNA sequencing. In
addition, these results may have implications for the nascent field of
“precision sarcoma medicine”. On the one hand, the “druggability” of
YAP1 suggests a rational strategy to selectively target FUS-DDIT3-
expressing MLS cells. Secondly, nuclear YAP1 expression may represent
a biomarker to identify MLS patients that could benefit from a YAP1-
directed therapeutic approach within future clinical trials.
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